GADA testing: the current state of knowledge.
This review considers the current knowledge and practice of GADA testing people with diabetes in Europe and the UK. Important issues are raised, including interpretation of the results and the clinical relevance of the GADA titre. Recommendations are made towards standardising GADA testing, using World Health Organization units.
Davies
H
H
Centre for Health Information, Research and Evaluation [CHIRAL], The School of Medicine, Swansea University, Singleton Park, Swansea SA2 8PP, United Kingdom. h.davies@swansea.ac.uk
Brophy
S
S
Bain
S C
SC
Stephens
J W
JW
Lewis
J
J
Luzio
S
S
Dunseath
G
G
Beaverstock
C
C
Williams
D R R
DR
D015415:Biomarkers / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood / Q000145:classification / Q000201:enzymology*; D005968:Glutamate Decarboxylase / Q000097:blood*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D012680:Sensitivity and Specificity
D015415:Biomarkers; D007004:Hypoglycemic Agents; D007328:Insulin; D005968:Glutamate Decarboxylase